Sanofi India Ltd held an earnings call on October 29, 2025, discussing its un-audited financial results and market strategies, particularly in the biosimilar segment and new potential market entries. The company maintains a 50% market share for Lantus despite the presence of biosimilars and aims to enhance its diabetes product portfolio.